logo
Plus   Neg
Share
Email

Astellas Pharma To Buy Audentes Therapeutics In $3 Bln Deal

Astellas Pharma Inc agreed to acquire Audentes Therapeutics Inc. (BOLD) for US$60.00 per share in cash, representing a total equity value of about US$3 billion.

The offer price represents a premium of 110% to Audentes' closing share price of US$28.61 on December 2, 2019.

Asilomar will commence a tender offer for all outstanding shares of common stock of Audentes. The Tender Offer period is expected to commence in the next few weeks and to expire 20 business days after its commencement, unless otherwise extended.

Astellas said it is still reviewing the impact of a consummation of the transaction on its financial results for the fiscal year ending March 31, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
3M rebuffed media reports over the alleged seizure of a shipment of N95 Respirators by U.S. authorities, saying there were a no evidence to suggest the Respirators were seized and diverted to the U.S. Lowe's (LOW) is temporarily increasing wages of its employees. The latest move by the hardware retailer is to help its employees cope with the economical effects caused by the ongoing COVID-19 pandemic. The company has hiked salary by $2 per hour for all full-time, part-time, and seasonal hourly associates,... Amazon.com Inc. (AMZN) Founder and CEO Jeff Bezos is donating $100 million to food banks across the U.S. to support poor people who cannot afford food during this coronavirus crisis. Bezos made a $100 million gift to Feeding America, one of the largest U.S. nonprofit focused on food security. Feeding...
RELATED NEWS
Follow RTT
>